A gRNA and kit for detecting hepatitis B virus drug resistance-related mutations

Through the gRNA design based on the Cas14a1 reporting system, the spacer sequence activates the DNA enzyme activity of Cas14a1, and high sensitivity and specific detection of the reverse transcriptase region of the HBV DNA polymerase gene is achieved, solving the high detection cost and sensitivity in the prior art The problem of insufficient is suitable for clinical applications.

CN115807127BActive Publication Date: 2024-11-22CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211168538.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-24
Publication Date
2024-11-22
Estimated Expiration
2042-09-24

AI Technical Summary

Technical Problem

The existing HBV drug tolerance-related mutation detection methods are costly, complex and not suitable for clinical promotion, especially the sensitivity and specificity of the detection of reverse transcriptase region of the DNA polymerase gene of hepatitis B virus.

Method used

A gRNA based on the Cas14a1 reporter system was designed to enable specific detection of the reverse transcriptase region of the HBV DNA polymerase gene, including multiple drug-resistant genes, by optimizing the spacer sequence and introducing additional mismatch. Identification of mutation sites.

Benefits of technology

It realizes high sensitivity and specific detection of the reverse transcriptase region of the HBV DNA polymerase gene, reduces the detection cost, is suitable for bedside diagnosis, and can detect corresponding mutations in a short time, and is suitable for large-scale clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115807127B_ABST
    Figure CN115807127B_ABST
Patent Text Reader

Abstract

The present invention provides a guide RNA (gRNA) and a kit for detecting drug tolerance-related mutations in the reverse transcriptase region (RT) of a hepatitis B virus DNA polymerase (DNA Polymerase) gene based on a Cas14a1 reporter system. The spacer sequence of the gRNA is a sequence shown in any one of SEQ ID No.1 to 11, SEQ ID No.13 to 15, SEQ ID No.17 to 21, or SEQ ID No.23 to 26. By introducing a base mismatch with a target sequence on a spacer sequence in a gRNA molecule, a highly specific and rapid detection of drug tolerance-related mutations in the reverse transcriptase region (RT region) of a hepatitis B virus DNA polymerase gene is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a gRNA and a kit for detecting drug resistance-related mutations in a reverse transcriptase region (RT region) of a hepatitis B virus DNA polymerase gene. Background Art

[0002] There are more than 240 million people chronically infected with hepatitis B virus (HBV) worldwide. Among chronic HBV infected people who do not receive treatment, 15% to 40% progress to cirrhosis, which may eventually lead to liver failure and liver cancer. Primary liver cancer (approximately 75%-90% of cases are hepatocellular carcinoma) is the second most common cause of cancer death in the world, and chronic HBV infection accounts for at least 50% of hepatocellular carcinoma cases. Hepatitis B virus is a small DNA virus. The infectious virus particles circulate in the form of 42nm Dan particles, which include a nucleocapsid composed of a lipid bilayer and proteins, and a 3.2kb partially double-stranded HBV genome inside the nucleocapsid. There are four open reading frames in the negative strand of the HBV genome, namely the S region, C region, P region, and X region. The P region is responsible for encoding HBV DNA polymerase, of which the reverse transcriptase region (reverse transcriptase, rt) encodes a protein with reverse transcriptase activity.

[0003] There are two types of drugs for the treatment of hepatitis B: interferon and nucleos(t)ideanalogues (NAs). Currently, the first-line drug for the treatment of hepatitis B is NAs, including L-nucleoside drugs: lamivudine (LA M), telbivudine (LdT); alkylphosphonates: adefovir dipivoxil (ADV), tenofovir disoproxil fumarate (TDF); cyclopentane drugs: entecavir (ETV). Nucleotide analogs (NAS) target HBV reverse transcriptase and need to be used for a long time to achieve the goal of reducing viral load to undetectable levels and sustained virological response. Due to the lack of a strict correction mechanism during HBV reverse transcription, the nucleotide mismatch rate is high. Over time, under the pressure selection of NAs, the HBV rt region is prone to mutations, namely genotype resistance mutations. These mutations may cause patients to lose sensitivity to these drugs, leading to resistance to antiviral drugs. The most common mutation sites associated with drug resistance in the reverse transcriptase region of the hepatitis B virus P gene (RT region, the encoding gene is shown in SEQ ID No. 28, and the amino acid sequence is shown in SEQ ID No. 29) are amino acids 169, 180, 181, 184, 202, 204, 236, and 250 in the RT region.

[0004] HBV drug resistance detection includes genotyping detection or phenotypic analysis. Phenotypic analysis of HBV drug resistance relies on cell culture and related technologies, which has high labor and technical requirements and is not suitable for high-throughput screening. Methods for detecting genotype drug resistance mutations include direct PCR sequencing, restriction fragment length polymorphism analysis (RFLP), inno-line probe assay (INNO-LiPA), matrix-assisted laser desorption / ionization time of flight mass spectrometry (MALDI-TOF-MS), real-time fluorescence PCR melting curve analysis, hybrid hybridization sequencing PCR (microsequencing), single genome sequencing, DNA chip technology, and genome deep sequencing. These methods are fast and accurate, but require expensive experimental equipment and well-trained professionals. They also have disadvantages such as high cost and complex data analysis, and are not suitable for clinical promotion and application. Due to the high rate of spontaneous mutation during HBV replication and the development and long-term use of multiple nucleotide analog drugs for the treatment of chronic hepatitis B, it is increasingly important to design an analytical method that can detect all known drug-resistant mutations.

[0005] Jennifer Doudna's team reported Cas14a-DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter), a highly sensitive nucleic acid molecule detection tool based on CRISPR-Cas14a1. The system includes Cas14a1, sequence-specific gRNA, ssDNA probe, and T7 exonuclease. A phosphorothioate (PT)-modified primer is introduced during the target DNA amplification process, and the amplified product is treated with T7 exonuclease. The single strands in the amplified product that are not modified by PT will be degraded, and a PT-modified ssDNA will be obtained as the detection target of the Cas14a1 reporter system. The gRNA used in the Cas14a1 system is composed of crRNA (CRISPR RNA) and tracrRNA (trans-activating crRNA), where crRNA consists of a fixed direct repeat sequence (direct repeat) and a target-specific spacer sequence (spacer). After Cas14a1 recognizes and cuts the target ssDNA under the guidance of gRNA, Cas14a1 exhibits DNA enzyme activity, exerts a secondary effect to non-specifically cut the ssDNA fluorescent probe, and releases a fluorescent signal. The intensity of the fluorescent signal is detected to determine whether the non-specific DNA enzyme activity of Cas14a1 is activated, and then to determine whether there is an ssDNA target matching the specific spacer sequence in the system. In addition to determining whether there is a DNA of a specific sequence, the degree of matching between the spacer and the target ssDNA is further optimized, and the system can also be further used to determine whether there is a specific single-base mutation in the sequence. Jennifer Doudna's team used this diagnostic technology to detect single-base mutations in the human E3 ubiquitin ligase (HERC2) gene. There is no report on the general design strategy of Cas14a1 gRNA for distinguishing single-base mutations, nor is there any literature on the use of this system for the identification of mutations associated with drug resistance of hepatitis B virus. Summary of the invention

[0006] The technical problem to be solved by the present invention is: how to provide a gRNA and a kit for detecting drug resistance-related mutations in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene.

[0007] The technical solution of the present invention is: a g RNA for detecting hepatitis B virus drug resistance-related mutations based on the Cas14a1 reporter system, wherein the gRNA is composed of a framework sequence that acts on the Cas14a1 enzyme and a target-specific spacer sequence, and the spacer sequence is a sequence shown in any one of SEQ ID No.1-11, SEQ ID No.13-15, SEQ ID No.17-21 or SEQ ID No.23-26.

[0008] Furthermore, the framework sequence that acts on the Cas14a1 enzyme is the nucleotide sequence shown in SEQ ID No.29.

[0009] A kit comprising the gRNA described above.

[0010] Furthermore, it also contains one or more of Cas14a1 enzyme, ssDNA fluorescent probe, T7 nuclease or nuclease buffer.

[0011] The inventors differentially activated the DNA enzyme activity of Cas14a1 by optimizing the relative position of the mutation site to be identified in the spacer sequence in the Cas14a1 system gRNA and appropriately introduced additional mismatches into the spacer sequence, thereby realizing the detection of single nucleotide mutations. Based on this academic idea, the drug tolerance-related mutations in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene were used as detection targets, and a set of gRNA sets that can be used for SNP identification based on the Cas14a1 detection system was demonstrated.

[0012] The gRNA forms complementarity with the 180th (L180M), 184th (T184L), 202nd (S202G), 204th (M204I, M204V) or 236th (N236T) amino acid mutant ssDNA of the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, and forms a single base mismatch with the wild-type ssDNA of the target gene. The gRNA forms a single base mismatch with the 169th (I169T), 181st (A181T, A181V), and 250th (M250L) amino acid mutant ssDNA of the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, and forms a double base mismatch with the wild-type ssDNA of the target gene.

[0013] The gRNA recognizes the mutant target ssDNA it targets, and the Cas14a1 protein is paired and bound to the corresponding ssDNA containing the mutation site under the guidance of the set gRNA, and Cas14a1 undergoes a conformational change to obtain non-specific ssDNA enzyme activity, and the Cas14a1 protein with ssDNA enzyme activity cuts the fluorescently labeled ssDNA probe to release a fluorescent signal; when the gRNA guidance system for a specific mutation is set to bind to the wild-type target ssDNA, the non-specific ssDN A enzyme activity of Cas14a1 cannot be well excited, so that the fluorescence signal difference of the wild-type target ssDNA and the mutant target ssDNA can be detected by the set gRNA-guided Cas14a1 system, and the mutant and wild-type sites can be distinguished, so as to detect the drug tolerance-related mutations in the reverse transcriptase region (Reverse transcriptase, RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, especially the drug tolerance-related mutations in the reverse transcriptase region (Reverse transcriptase, RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene caused by mutations in a single base.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] (1) The present invention provides a gRNA that can specifically target multiple drug-resistant gene mutation sites (amino acids 169, 180, 181, 202, 204, 236, and 250) in the RT region of the P gene of hepatitis B virus and activate the ssDNA enzyme activity of the CRISP R-Cas14a1 system, and can specifically detect drug-resistant gene mutation sites.

[0016] (2) The present invention does not require a sequencer or a fluorescent quantitative PCR instrument to detect drug resistance-related mutations in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene. It only requires the use of simple instruments such as a fluorescent microplate reader or naked eye observation methods such as colloidal gold to determine whether the ssDNA enzyme activity of Cas14a1 is activated, which can be applied to subsequent point of care (POCT) detection methods.

[0017] (3) The present invention detects common mutation sites in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, achieving a relatively comprehensive detection effect.

[0018] (4) The method of the present invention has low detection cost, can be repeatedly detected, and the results can be analyzed intuitively (for example, by fluorescence reading), and is suitable for large-scale clinical application.

[0019] (5) The present invention improves the sensitivity and specificity of detecting drug resistance-related mutations in the reverse transcriptase region (RT) of the DNA polymerase gene of hepatitis B virus and shortens the time required for detection. The present invention has high detection sensitivity (the minimum detection limit reaches 1×10 0 The detection speed is fast, and the corresponding mutation can be detected in a short time (when the reaction is carried out for 30 minutes, the fluorescence signal of the mutant target ssDNA is significantly higher than that of the wild-type target ssDNA). BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 For Example 1 of the present invention: A is directed to the detection of amino acid mutations at position 180 (L180M), position 184 (T184L), position 202 (S202G), position 204 (M204I, M204V), and position 236 (N236T) of the reverse transcriptase (RT) region of the DNA polymerase (DNA Polymerase) gene of hepatitis B virus, L180M-9 gRNA, T184L-9 gRNA, S202G-9 gRNA, M204I-9 gRNA, M204V-9 gRNA, N236T-9 g A RNA detected the wild-type target and the targets with amino acid mutations at position 180 (L180M), position 184 (T184L), position 202 (S202G), position 204 (M204I, M204V), and position 236 (N236T) in the RT region; B detected the amino acid mutations at position 180 (L180M), position 184 (T184L), position 202 (S202G), position 204 (M204I, M204V), and position 236 (N236T) in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, L180M-9 gRNA, T184L-9 gRNA, S202G-9 gRNA, M204I-9 gRNA, M204V-9 gRNA, N236T-9 The fluorescence signal ratios of mutant target ssDNA and wild-type target ssDNA were detected by gRNA respectively; (n=3 technical replicates; bar represents mean±SD);

[0021] Figure 2 This is Example 2 of the present invention: A is for detecting the 169th amino acid mutation (I169T) in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, and I169T 9+3 gRNA, I169T 9+8 gRNA, I169T 9+10 gRNA, I169T 9+13 gRNA, and I169T 9+18 gRNA detect the wild-type target and the target with the 169th amino acid mutation in the RT region, respectively; B is for detecting the 169th amino acid mutation (I169T) in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, and I169T 9+3 gRNA, I169T 9+8 gRNA, I169T 9+10 gRNA, I169T 9+13 gRNA, and I169T 9+18 The fluorescence signal ratio of mutant target ssDNA and wild-type target ssDNA detected by gRNA respectively; (n=3 technical replies; bar represents mean±SD);

[0022] Figure 3 Embodiment 3 of the present invention: A is for detecting the 181st amino acid mutation (A181T) in the reverse transcriptase region (RT) of the DNA polymerase (DNA Polymerase) gene of hepatitis B virus, and A181T 9+3 gRNA, A181T 9+8 gRNA, A181T 9+10 gRNA, A181T 9+13 gRNA, and A181T 9+18 gRNA detect the wild-type target and the target with the 181st amino acid mutation in the RT region, respectively; B is for detecting the 181st amino acid mutation (A18 1T) in the reverse transcriptase region (RT) of the DNA polymerase (DNA Polymerase) gene of hepatitis B virus, and A181T 9+3 gRNA, A181T 9+8 gRNA, A181T 9+10 gRNA, A181T 9+13 gRNA, and A181T 9+18 The fluorescence signal ratio of mutant target ssDNA and wild-type target ssDNA was detected by gRNA respectively; (n=3 technical replicates; bar represents mean±SD);

[0023] Figure 4Embodiment 4 of the present invention: A is for the detection of the 181st amino acid mutation (A181V) in the reverse transcriptase region (Reverse transcriptase, RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, A181V 9+3 gRNA, A181V 9+8 gRNA, A181V 9+10 gRNA, A181V 9+13 gRNA, A181V 9+18 gRNA detect the wild-type target and the target with the 181st amino acid mutation in the RT region, respectively; B is for the detection of the 181st amino acid mutation (A18 1V) in the reverse transcriptase region (Reverse transcriptase, RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene, A181V 9+3 gRNA, A181V 9+8 gRNA, A181V 9+10 gRNA, A181V 9+13 gRNA, A181V 9+18 The fluorescence signal ratio of mutant target ssDNA and wild-type target ssDNA was detected by gRNA respectively; (n=3 technical replicates; bar represents mean±SD);

[0024] Figure 5 Embodiment 5 of the present invention: A is for detecting the 250th amino acid mutation (M250L) in the reverse transcriptase region (RT) of the DNA polymerase (DNA Polymerase) gene of hepatitis B virus, and M250L 9+3 gRNA, M250L 9+8 gRNA, M250L 9+10 gRNA, M250L 9+13 gRNA, and M250L 9+18 gRNA detect the wild-type target and the target with the 250th amino acid mutation in the RT region, respectively; B is for detecting the 250th amino acid mutation (M250L) in the reverse transcriptase region (RT) of the DNA polymerase (DNA Polymerase) gene of hepatitis B virus, and M250L 9+3 gRNA, M250L 9+8 gRNA, M250L 9+10 gRNA, M250L 9+13 gRNA, and M250L 9+18 The fluorescence signal ratios of mutant target ssDNA and wild-type target ssDNA were detected by gRNA respectively; (n=3 technical replicates; bar represents mean±SD).

[0025] Figure 6 The sensitivity of the gRNA of the present invention in detecting the corresponding mutation site. DETAILED DESCRIPTION

[0026] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from commercial channels unless otherwise specified.

[0027] Example 1

[0028] 1. Design gRNA for the detection of amino acid mutations at position 180 (L180M), position 184 (T184L), position 202 (S202G), position 204 (M204I, M204V), and position 236 (N236T) in the reverse transcriptase region (RT) of the DNA polymerase gene of hepatitis B virus

[0029] (1) Screening principles:

[0030] The principle of designing the spacer sequence part of the designed gRNA is to adjust the number and relative positions of bases in the spacer sequence that do not match the wild-type target ssDNA, so that the selected gRNA for a specific mutation cannot recognize the wild-type target ssDNA or has a low level of recognition, but efficiently recognizes the corresponding mutant ssDNA, thereby releasing the non-specific ssDNA enzyme activity of Cas14a1.

[0031] (2) Selection of gRNA sequence:

[0032] According to the site where the mutation occurs, the length of the gRNA spacer sequence is 20 nucleotides (nt). For the mutation at position 180 (mutation form Leu-Met, base mutation type CTG-ATG), a gRNA guide sequence targeting it (SEQ ID No. 1) is designed. The spacer sequence and its target sequence are shown in the following table, where the bold underlined part is the mutation site. Among them, the gRNA spacer is 20nt, and the 9th base of the spacer is complementary to the mutant target ssDNA. The type of gRNA that does not match the wild-type target ssDNA (i.e., L180M-9 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 1 ).

[0033]

[0034] For the mutation at position 184 (mutation form Thr-Leu, base mutation type AC T- CTT), the mutation type is a double base mutation, and a gRNA guide sequence targeting it (SEQ ID No. 2) is designed. The spacer sequence and the target sequence it targets are shown in the following table, where the bold underlined part is the mutation site. Among them, the gRNA spacer is 20nt, and the 9th and 10th bases of the spacer are complementary to the mutant target ssDNA. The type of gRNA that does not match the wild-type target ssDNA (i.e., T184L-9 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 1 ).

[0035]

[0036] For the mutation at position 202 (mutation form Ser-Gly, base mutation type AGT-GGT), a gRNA guide sequence targeting it (SEQ ID No. 3) was designed. The spacer sequence and the target sequence it targets are shown in the following table, where the bold underlined part is the mutation site. Among them, the spacer of the gRNA is 20 nt, and the 9th base of the spacer is complementary to the mutant target ssDNA. The type of gRNA that does not match the wild-type target ssDNA (i.e., S202G-9 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 1 ).

[0037]

[0038] For the mutation at position 204 (mutation form Met-Ile, base mutation type AT G -AT T ), a gRNA guide sequence targeting it (SEQ ID No. 4) was designed, and the spacer sequence and the target sequence it targets are shown in the following table, where the bold underlined part is the mutation site. Among them, the gRNA spacer is 20nt, and the 9th base of the spacer is complementary to the mutant target ssDNA. The type of gRNA that does not match the wild-type target ssDNA (i.e., M204I-9 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 1 ).

[0039]

[0040] For the mutation at position 204 (mutation form Met-Val, base mutation type A TG- GTG), designed a gRNA guide sequence targeting it (SEQ ID No.5), the spacer sequence and its target sequence are shown in the following table, where the bold underlined part is the mutation site. Among them, the gRNA spacer is 20nt, the 9th base of the spacer is complementary to the mutant target ssDNA, and the type of gRNA that does not match the wild-type target ssDNA (i.e., M204V-9 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 1 ).

[0041]

[0042] For the mutation at position 236 (mutation form Asn-Thr, base mutation type A A CA C C), designed a gRNA guide sequence targeting it (SEQ ID No.6), the spacer sequence and the target sequence it targets are shown in the following table, where the bold underlined part is the mutation site. Among them, the gRNA spacer is 20nt, the 9th base of the spacer is complementary to the mutant target ssDNA, and the type of gRNA that does not match the wild-type target ssDNA (i.e., N236T-9 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 1 ).

[0043]

[0044] 2. Preparation of mutant target DNA (ssDNA) and gRNA

[0045] Synthesis of wild-type and mutant target DNA:

[0046] A plasmid containing a wild-type target gene sequence is synthesized, and site-directed mutagenesis is performed on the plasmid containing the wild-type target gene sequence to obtain a plasmid containing a mutant target gene sequence.

[0047] PCR amplification was performed using primers modified with phosphorothioate (PT) to obtain mutant target dsDNA.

[0048] The above-mentioned PCR product dsDNA is added as a detection substrate into the subsequent CRISPR-Cas14a1 detection system. The chain in the PCR product that is not modified by PT is degraded from the 5' end to the 3' end under the action of T7 nuclease, while the chain amplified by the PT-modified primer can resist the action of nuclease and be retained, that is, the target ssDNA is obtained.

[0049] Synthesis of gRNA:

[0050] The corresponding DNA sequence was determined according to the tracrRNA sequence in Cas14a1 gRNA, the direct repeat sequence of crRNA, and the designed specific spacer sequence, and the T7 RNA polymerase promoter sequence was added to the 5' end to construct the target DNA fragment required for subsequent transcription of gRNA. The fragment was constructed into a prokaryotic expression vector to obtain a DNA recombinant plasmid corresponding to the target gRNA.

[0051] The above recombinant plasmid was used as a template to amplify the target DNA fragment by PCR, and the PCR product was purified.

[0052] The purified PCR product was used as a template for in vitro RNA transcription.

[0053] Example of a 20 μL transcription system: dNTP 1.5 μL each, 10×Reaction Buffer 1.5 μL, T7 RNApolymerase Mix 1.5 μL, template 1 μg, DDT 5 mM, add enzyme-free water to 20 μL, 37°C, 16 h, then add DNase I (5 U / μl) 2 μL (37°C, 15 mins), and purify to obtain gRNA (composed of a relatively conservative framework sequence SEQ ID No. 27 that can act with the Cas14a1 enzyme + a specific spacer sequence).

[0054] 3. Prokaryotic expression and purification of Cas14a1 protein

[0055] Use pLBH531_MBP-Cas14a1 expression plasmid and E. coli expression system: Use heat shock method to transform pLBH531_MBP-Cas14a1 expression plasmid vector into E. coli competent cells, pick positive colonies and inoculate them into TB liquid culture medium for bacterial enrichment culture (220rpm, 37℃), when OD600 value rises to 0.5, add IPTG with a final concentration of 500μmol / L to induce expression, and continue overnight culture (220rpm, 18℃).

[0056] Escherichia coli cultured overnight were collected and resuspended in Lysis buffer (pH 8.0, 50mmol / L Tris-HCl, 500mmol / L NaCl, 0.5mmol / L TCEP). After ultrasonic bacterial lysis, the supernatant was collected by centrifugation (10000rpm, 1h) and filtered with a 0.22μm sterilization filter. The supernatant was added to a Ni-NTA agarose gel (His tag purification resin) chromatography column, mixed with the resin thoroughly, and the sample was collected after standing for 20min, and then eluted step by step with Wash buffer (pH 8.0, 50mmol / LTris-HCl, 500mmol / L NaCl, 0.5mmol / L TCEP, 20mmol / Limidazole) and Elution buffer (pH8.0, 50mmol / L Tris-HCl, 500mmol / L NaCl, 0.5mmol / L TCEP, 300mmol / Limidazole). After elution, the sample was collected and added to a protein concentrator tube PES (Thermo Scientific, 88516) for centrifugation and concentration (4°C, 4000 g, 20 min). During the concentration process, the sample was exchanged to Buffer A (pH 7.5, 20 mmol / L HEPES, 0.5 mmol / L TCEP, 150 mmol / L NaCl). TEV protease was added and incubated at 4°C overnight. The sample was replaced from Buffer A to Buffer B (pH 7.5, 20mmol / L HEPES, 0.5mmol / L TCEP, 1250mmol / L NaCl) and collected after linear gradient elution through an MBP column and a heparin affinity purification column. The purified Cas14a1 protein was verified by SDS-PAGE electrophoresis, concentrated by centrifugation, dialyzed overnight at 4°C into Storage buffer (pH 7.5, 50mmol / L Tris-HCl, 500mmol / L NaCl, 0.5mmol / L TCEP, 5% glycerol), and finally frozen in a -80°C refrigerator for use.

[0057] 4. Establishment of CRISPR-Cas14a1 system detection system

[0058] Prepare 40 μL of detection reaction system: 600 nM Cas14a1, 180 nM gRNA, 2250 nM ssDNA fluorescent reporter molecule ( / 56-FAM / TTTTTTTTTTTT / 3BHQ1 / ), 250 U / mL T7 exonuclease (NEB, M0263L), 4 μL 10xNEB Buffer 4 (B7004S), and add different amounts of target DNA molecules.

[0059] The Cas14a1, gRNA, T7 exonuclease and fluorescent reporter molecule can be prepared into an integrated detection kit.

[0060] The reaction system was incubated at 37°C for 60-120 minutes, during which the fluorescence value was detected every 1 minute. The ssDNA enzyme activity of Cas14a1 was determined by fluorescence readings, indicating the ability of a specific gRNA to guide Cas14a1 to bind to the target ssDNA. The wild-type target ssDNA was used as a template and the same gRNA was used to obtain the fluorescence value. The signal ratio obtained by the same gRNA-guided system to recognize mutant target ssDNA and wild-type target ssDNA was compared to obtain the ability of a specific gRNA to report a specific single-base mutation.

[0061] 5. Test results

[0062] The results of amino acid mutation detection at position 180 (L180M), position 184 (T184L), position 202 (S202G), position 204 (M204I, M204V), and position 236 (N236T): Figure 1 The fluorescence values ​​(fluorescence value entering the plateau phase - system background fluorescence value) of the amino acid changes at position 180 (L180M), position 184 (T184L), position 202 (S202G), position 204 (M204I, M204V), and position 236 (N236T) of the reverse transcriptase (RT) region of the hepatitis B virus DNA polymerase (DNA Polymerase) gene were detected using the specified gRNA to guide the CRISPR-Cas14a1 system. When the gRNA designed by targeting the amino acid changes at position 180 (L180M), position 184 (T184L), position 202 (S202G), position 204 (M204I, M204V), and position 236 (N236T) of the reverse transcriptase (RT) region of the hepatitis B virus DNA polymerase gene was used to guide the CRISPR-Cas14a1 system to detect mutant target ssDNA and wild-type target ssDNA, as shown in the results, at 30-40 minutes of detection, the fluorescence signal of the mutant target ssDNA guided by different gRNA systems was significantly higher than that of the wild-type ssDNA ( Figure 1In A and B, the signal ratios are L180M-9 gRNA: 88.26±10.31, T184L-9 gRNA: 47.73±12.78, S202G-9 gRNA: 46.43±5.01, M204I-9 gRNA: 112.1±7.95, M204V-9 gRNA: 59.74±2.10, N236T-9 gRNA: 16.13±1.69). When the ratio of the fluorescence signal obtained by the specific gRNA guide system to recognize the mutant target ssDNA and the signal obtained by its guide system to recognize the wild-type target ssDNA is greater than or equal to 2, it is considered that the gRNA can distinguish between the mutant sequence and the wild-type sequence.

[0063] In summary, when the mismatched base is located at the 9th position of the 5th end of the gRNA spacer sequence, the gRNA-guided CRISPR-Cas14a1 system targeting the amino acid changes at positions 180 (L180M), 184 (T184L), 202 (S202G), 204 (M204I, M204V), and 236 (N236T) of the reverse transcriptase (RT) region of the hepatitis B virus DNA polymerase gene can distinguish these six mutation types.

[0064] Example 2

[0065] 1. Design gRNA for the detection of mutation at position 169 (I169T) in the reverse transcriptase region (RT) of the DNA polymerase gene of hepatitis B virus

[0066] (1) The design principles are the same as those of Example 1.

[0067] (2) Selection of gRNA sequence:

[0068] According to the site of mutation, the length of the gRNA spacer is 20 nucleotides (nt). For the mutation at position 169 (mutation form Ile-Thr, base mutation type ATT-ACT), 5 gRNA guide sequences targeting it (SEQ ID No.7 to SEQ ID No.11) were designed. The spacer sequences and their target sequences are shown in the table below, where the bold underlined part is the mutation site.

[0069]

[0070]

[0071] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 3rd base of the spacer (i.e., I169T 9+3 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 2 ).

[0072]

[0073] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 8th base of the spacer (i.e., I169T 9+8 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 2 ).

[0074]

[0075] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 10th base of the spacer (i.e., I169T 9+10 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 2 ).

[0076]

[0077] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 13th base of the spacer (i.e., I169T 9+13 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 2 ).

[0078]

[0079] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 18th base of the spacer (i.e., I169T 9+18 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 2 ).

[0080] 2. Preparation of Mutation Target DNA (ssDNA) and gRNA

[0081] The method is the same as that in Example 1, and the synthesis of the mutation target ssDNA and the synthesis of the gRNA are performed for the 169th mutation.

[0082] 3. Prokaryotic expression and purification of Cas14a1 protein

[0083] Same as Example 1.

[0084] 4. Establishment of CRISPR-Cas14a1 system detection system

[0085] Same as Example 1.

[0086] 5. Test results

[0087] Mutation detection results at position 169 (I169T): Figure 2 The fluorescence value (fluorescence value entering the plateau phase minus the system background fluorescence value) (background-subtracted fluorescence) of the 169th (I169T) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene was detected using the specified gRNA to guide the CRISPR-Cas14a1 system.

[0088] When the gRNA designed to target the 169th position (I169T) mutation of the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene was used to guide the CRISPR-Cas14a1 system to detect mutant target ssDNA and wild-type target ssDNA, as shown in the results, at 30-40 minutes of detection, the fluorescence signal of the mutant target ssDNA by different gRNA-guided systems was significantly higher than that of the wild-type target ssDNA ( Figure 2In A and B, the signal ratios are I169T 9+3 gRNA: 49.13±6.36, I169T 9+8 gRNA: 93.79±9.15, I169T 9+10 gRNA: 13.88±2.89, I169T 9+13 gRNA: 2.14±0.78, I169T 9+18 gRNA: 3.69±0.45, respectively. If the ratio of the fluorescence signal obtained by the specific gRNA guide system to recognize the mutant ssDNA and the signal obtained by its guide system to recognize the wild-type ssDNA is greater than or equal to 2, it is considered that the gRNA can distinguish between the mutant sequence and the wild-type sequence.

[0089] In summary, the five gRNAs targeting the 169th (I169T) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase gene can distinguish mutations at this position. The gRNA type whose base at the 9th position of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and whose base at the 8th position of the spacer does not match both the wild-type and mutant target ssDNA (i.e., I169T9+8 gRNA) has the best detection effect.

[0090] Example 3

[0091] 1. Design gRNA for the detection of mutation at position 181 (A181T) in the reverse transcriptase region (RT) of the DNA polymerase gene of hepatitis B virus

[0092] (1) The design principles are the same as those of Example 1.

[0093] (2) Selection of gRNA sequence:

[0094] According to the site of mutation, the length of the gRNA spacer is 20 nucleotides (nt). For the mutation at position 181 (mutation form Ala-Thr, base mutation type GCT-ACT), 5 gRNA guide sequences targeting it (SEQ ID No.12 to SEQ ID No.16) were designed. The spacer sequences and their target sequences are shown in the table below, where the bold underlined part is the mutation site.

[0095]

[0096] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 3rd base of the spacer (i.e., A181T 9+3 gRNA) cannot distinguish the wild-type and mutant target genes well (discrimination ability see Figure 3 ).

[0097]

[0098] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 8th base of the spacer (i.e., A181T 9+8 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 3 ).

[0099]

[0100] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 10th base of the spacer (i.e., A181T 9+10 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 3 ).

[0101]

[0102] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 13th base of the spacer (i.e., A181T 9+13 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 3 ).

[0103]

[0104] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the 18th base of the spacer and the wild-type and mutant target ssDNA (i.e., A181T 9+18 gRNA) cannot distinguish the wild-type and mutant target genes well (discrimination ability see Figure 3 ).

[0105] 2. Preparation of Mutation Target DNA (ssDNA) and gRNA

[0106] The method is the same as that in Example 1, and the synthesis of the mutation target ssDNA and gRNA is performed for the 181st mutation (A181T).

[0107] 3. Prokaryotic expression and purification of Cas14a1 protein

[0108] Same as Example 1.

[0109] 4. Establishment of CRISPR-Cas14a1 system detection system

[0110] Same as Example 1.

[0111] 5. Test results

[0112] Mutation detection results at position 181 (A181T): Figure 3 The fluorescence value (fluorescence value entering the plateau phase minus the system background fluorescence value) (background-subtracted fluorescence) of the 181st (A181T) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene was detected using the specified gRNA to guide the CRISPR-Cas14a1 system.

[0113] When the gRNA designed to target the 181st (A181T) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene was used to guide the CRISPR-Cas14a1 system to detect mutant target ssDNA and wild-type target ssDNA, as shown in the results, at 30-40 minutes of detection, the fluorescence signal of the mutant target ssDNA by different gRNA-guided systems was significantly higher than that of the wild-type target ssDNA ( Figure 3In A and B, the signal ratios are A181T 9+3 gRNA: 1.34±0.06, A181T 9+8 gRNA: 110.20±10.73, A181T 9+10 gRNA: 4.38±1.53, A181T 9+13 gRNA: 2.20±0.38, A181T 9+18 gRNA: 1.56±0.33). If the ratio of the fluorescence signal obtained by the specific gRNA guide system to recognize the mutant target ssDNA and the signal obtained by its guide system to recognize the wild-type target ssDNA is greater than or equal to 2, it is considered that the gRNA can distinguish between the mutant sequence and the wild-type sequence.

[0114] In summary, among the five gRNAs targeting the 181st (A181T) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase gene, three guided the CRISPR-Cas14a1 system to distinguish the mutation at this position, among which the 9th base of the spacer was complementary to the mutant target ssDNA and did not match the wild-type target ssDNA, and the type of gRNA that did not match the 8th base of the spacer and both the wild-type and mutant target ssDNA (i.e., A181T 9+8 gRNA) had the best detection effect.

[0115] Example 4

[0116] 1. Design of gRNA for the detection of mutation at position 181 (A181V) in the RT region of the P gene of hepatitis B virus

[0117] (1) The design principles are the same as those of Example 1.

[0118] (2) Selection of gRNA sequence:

[0119] According to the site of mutation, the length of the gRNA spacer sequence is 20 nucleotides (nt). For the mutation at position 181 (mutation form Ala-Val, base mutation type GCT-GTT-), 5 gRNA guide sequences targeting it (SEQ ID No.17 to SEQ ID No.21) were designed. The spacer sequences and their target sequences are shown in the following table, where the bold underlined part is the mutation site.

[0120]

[0121]

[0122] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 3rd base of the spacer (i.e., A181V 9+3 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 4 ).

[0123]

[0124] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 8th base of the spacer (i.e., A181V 9+8 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 4 ).

[0125]

[0126] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 10th base of the spacer (i.e., A181V 9+10 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 4 ).

[0127]

[0128] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 13th base of the spacer (i.e., A181V 9+13 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 4 ).

[0129]

[0130] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 18th base of the spacer (i.e., A181V 9+18 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 4 ).

[0131] 2. Preparation of Mutation Target DNA (ssDNA) and gRNA

[0132] The method is the same as that in Example 1, and the synthesis of the mutant target ssDNA and the synthesis of the gRNA are performed for the 181st mutation (A181V).

[0133] 3. Prokaryotic expression and purification of Cas14a1 protein

[0134] Same as Example 1.

[0135] 4. Establishment of CRISPR-Cas14a1 system detection system

[0136] Same as Example 1.

[0137] 5. Test results

[0138] Mutation detection results at position 181 (A181V): Figure 4 The fluorescence value (fluorescence value entering the plateau phase minus the system background fluorescence value) (background-subtracted fluorescence) of the 181st (A181V) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene was detected using the specified gRNA to guide the CRISPR-Cas14a1 system.

[0139] When gRNA was designed targeting the 181st (A181V) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene to guide the CRISPR-Cas14a1 system to detect mutant target ssDNA and wild-type target ssDNA, as shown in the results, at 30-40 minutes of detection, the fluorescence signal of the mutant target ssDNA by different gRNA-guided systems was significantly higher than that of the wild-type target ssDNA ( Figure 4In A and B, the signal ratios are A181V 9+3 gRNA: 5.73±0.97, A181V 9+8 gRNA: 40.84±7.41, A181V 9+10 gRNA: 35.78±2.30, A181V 9+13 gRNA: 37.08±5.09, A181V 9+18 gRNA: 126.61±6.22, respectively. If the ratio of the fluorescence signal obtained by the specific gRNA guide system to recognize the mutant target ssDNA and the signal obtained by its guide system to recognize the wild-type target ssDNA is greater than or equal to 2, it is considered that the gRNA can distinguish between the mutant sequence and the wild-type sequence.

[0140] In summary, the five gRNAs targeting the 181st (A181V) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase gene can distinguish the position of the gRNA, among which the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the 8th base of the spacer and both the wild-type and mutant target ssDNA (i.e., A181V9+8 gRNA) has the best detection effect.

[0141] Example 5

[0142] 1. Design gRNA for the detection of mutation at position 250 (M250L) in the RT region of the P gene of hepatitis B virus

[0143] (1) The design principles are the same as those of Example 1.

[0144] (2) Selection of gRNA sequence:

[0145] According to the site of mutation, the length of the gRNA spacer is 20 nucleotides (nt). For the mutation at position 250 (mutation form Met-Leu, base mutation type ATG-CTG), 5 gRNA guide sequences targeting it (SEQ ID No. 22 to SEQ ID No. 26) were designed. The spacer sequences and their target sequences are shown in the table below, where the bold underlined part is the mutation site.

[0146]

[0147] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 3rd base of the spacer (i.e., M250L 9+3 gRNA) cannot distinguish the wild-type and mutant target genes well (discrimination ability see Figure 5 ).

[0148]

[0149] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 8th base of the spacer (i.e., M250L 9+8 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 5 ).

[0150]

[0151] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 10th base of the spacer (i.e., M250L 9+10 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 5 ).

[0152]

[0153] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 13th base of the spacer (i.e., M250L 9+13 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 5 ).

[0154]

[0155] Among them, the gRNA spacer is 20 nt, the 9th base of the spacer is complementary to the mutant target ssDNA and does not match the wild-type target ssDNA, and the type of gRNA that does not match the wild-type and mutant target ssDNA at the 18th base of the spacer (i.e., M250L 9+18 gRNA) can distinguish between wild-type and mutant target genes (discrimination ability see Figure 5 ).

[0156] 2. Preparation of Mutation Target DNA (ssDNA) and gRNA

[0157] The method is the same as that in Example 1, and the synthesis of mutation target ssDNA and gRNA is performed for the 250th mutation (M250L).

[0158] 3. Prokaryotic expression and purification of Cas14a1 protein

[0159] Same as Example 1.

[0160] 4. Establishment of CRISPR-Cas14a1 system detection system

[0161] Same as Example 1.

[0162] 5. Test results

[0163] Results of mutation detection at position 250 (M250L): Figure 5 The fluorescence value (fluorescence value entering the plateau phase minus the system background fluorescence value) (background-subtracted fluorescence) corresponding to the mutation of the 250th (M250L) amino acid substitution in the reverse transcriptase (RT) region of the DNA polymerase (DNA Polymerase) gene of the hepatitis B virus was detected using the specified gRNA to guide the CRISPR-Cas14a1 system.

[0164] When gRNA was designed targeting the 250th position (M250L) mutation of the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase (DNA Polymerase) gene to guide the CRISPR-Cas14a1 system to detect mutant target ssDNA and wild-type target ssDNA, as shown in the results, at 30-40 minutes of detection, the fluorescence signal of the mutant target ssDNA by different gRNA-guided systems was significantly higher than that of the wild-type target ssDNA ( Figure 5In A and B, the signal ratios are M250L 9+3 gRNA: 1.80±0.43, M250L 9+8 gRNA: 70.40±14.49, M250L 9+10 gRNA: 11.35±0.96, M250L 9+13 gRNA: 5.65±0.36, M250L 9+18 gRNA: 10.36±4.57, respectively. If the ratio of the fluorescence signal obtained by the specific gRNA guide system to recognize the mutant target ssDNA and the signal obtained by its guide system to recognize the wild-type target ssDNA is greater than or equal to 2, it is considered that the gRNA can distinguish between the mutant sequence and the wild-type sequence.

[0165] In summary, among the five gRNAs targeting the 250th (M250L) mutation in the reverse transcriptase region (RT) of the hepatitis B virus DNA polymerase gene, four guided the CRISPR-Cas14a1 system to distinguish the mutation at this position, among which the 9th base of the spacer was complementary to the mutant target ssDNA and did not match the wild-type target ssDNA, and the type of gRNA that did not match the 8th base of the spacer and both the wild-type and mutant target ssDNA (i.e., M250L 9+8 gRNA) had the best detection effect.

[0166] Example 6 Detection sensitivity results

[0167] Sensitivity assessment: The constructed wild-type and mutant plasmids were adjusted to the same concentration, ranging from 1×10 6 copies / μL, and dilute with sterile enzyme-free water to prepare 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 The template of 500 copies / μL was used for PCR reaction, and 5μL of PCR product was taken for detection using the Cas14a1 reporter system method established in this paper, and the fluorescence intensity difference between wild-type and mutant HBV at each mutation site was compared. The fluorescence values ​​of mutant plasmid detection and wild-type plasmid detection at each concentration were statistically analyzed, and the lowest concentration with statistical difference was considered to be the sensitivity of gRNA detection at the corresponding mutation site in this paper. Figure 6 The integrated detection system provides a sensitivity of 1×10 0 copies / μL to 1×10 2 copies / μL.

[0168] Clinical performance evaluation A total of 60 sera from hepatitis B patients were collected, and viral DNA in the serum was extracted as a template using a viral DNA extraction kit. 50 μL of PCR reaction system was added according to 15 μL. After PCR amplification of the sequence fragment of the reverse transcriptase region (RT) of the DNA polymerase (DNA Polymerase) gene of hepatitis B virus, Sanger sequencing was performed to obtain mutation information and mutation detection was performed using gRNA targeting different mutations according to the method described above. At least one of the above 10 types of drug resistance-related mutations in the reverse transcriptase region (RT) of the DNA polymerase (DNA Polymerase) gene of hepatitis B virus was defined as a positive sample, and no mutation type was detected as a negative sample. Sanger sequencing was used as the gold standard for genetic testing, and 39 positive samples and 21 negative samples were detected. The Cas14a1 reporter system method established in this article detected 40 positive samples and 20 negative samples. The results are shown in the following table. Except for one sample that was judged as negative based on Sanger sequencing but positive by the Cas14a1 reporter system, the results of drug resistance-related mutations in the reverse transcriptase region (RT) of the DNA polymerase (DNA Polymerase) gene of the remaining samples by the two methods were consistent. The consistency of the method established in this article with the gold standard Sanger sequencing results was 98.33%. G CT- A FastNGS high-throughput sequencing was performed on an inconsistent sample of hepatitis B virus (HBV) from the same sample. The mutation detection results were consistent with the Cas14a1 reporter system method established in this paper. The fastNGS high-throughput sequencing results indicated that the rtA181T type mutation occurring at the rt181 position of the reverse transcriptase (RT) region of the hepatitis B virus DNA polymerase (DNA Polymerase) gene extracted from the sample was a low-frequency mutation (G:144, A:69).

[0169] Table 1. Summary of clinical evaluation results

[0170]

[0171] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for detecting gRNA for hepatitis B virus drug resistance-related mutations based on the Cas14a1 reporter system, characterized in that: The gRNA consists of a framework sequence that acts on the Cas14a1 enzyme and a target-specific spacer sequence, and the spacer sequence is a nucleotide sequence shown in any one of SEQ ID No.8, SEQ ID No.13, SEQ ID No.18 or SEQ ID No.

23.

2. The method for detecting hepatitis B virus drug resistance-related mutation gRNA based on the Cas14a1 reporter system according to claim 1, characterized in that The framework sequence that acts on the Cas14a1 enzyme is the nucleotide sequence shown in SEQ ID No.

27.

3. A kit comprising the gRNA according to claim 1 or 2.

4. The kit according to claim 3, characterized in that It also contains one or more of Cas14a1 enzyme, fluorescently labeled ssDNA probe, T7 exonuclease or nuclease buffer.